NO2881536T3 - - Google Patents

Info

Publication number: NO2881536T3
Authority: NO; Norway

Application number

NO14196403A

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-04-06

Filing date

2014-12-04

Publication date

2018-06-30

2014-12-04 Application filed filed Critical

2018-06-30 Publication of NO2881536T3 publication Critical patent/NO2881536T3/no

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Immunology (AREA)
Engineering & Computer Science (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Hematology (AREA)
Diabetes (AREA)
Microbiology (AREA)
Mycology (AREA)
Epidemiology (AREA)
Endocrinology (AREA)
Urology & Nephrology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicinal Preparation (AREA)
Mechanical Treatment Of Semiconductor (AREA)

NO14196403A 2012-04-06 2014-12-04 NO2881536T3 (no)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US201261621461P	2012-04-06	2012-04-06

Publications (1)

Publication Number	Publication Date
NO2881536T3 true NO2881536T3 (no)	2018-06-30

Family

ID=49325295

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO14196403A NO2881536T3 (no)	2012-04-06	2014-12-04

Country Status (29)

Country	Link
US (3)	US20130273053A1 (no)
EP (2)	EP2833907B1 (no)
JP (3)	JP6366571B2 (no)
KR (2)	KR102318623B1 (no)
CN (1)	CN104661676A (no)
AU (3)	AU2013267909B2 (no)
BR (1)	BR112014024793A2 (no)
CA (2)	CA2869326C (no)
CL (1)	CL2014002694A1 (no)
CY (1)	CY1120736T1 (no)
DK (2)	DK3366307T3 (no)
ES (2)	ES2670668T3 (no)
HK (1)	HK1206996A1 (no)
HR (1)	HRP20180671T1 (no)
HU (1)	HUE036930T2 (no)
IL (2)	IL234991B (no)
IN (1)	IN2014KN02324A (no)
LT (1)	LT2833907T (no)
MX (2)	MX357540B (no)
NO (1)	NO2881536T3 (no)
NZ (2)	NZ629675A (no)
PL (2)	PL3366307T3 (no)
PT (1)	PT2833907T (no)
RS (1)	RS57266B1 (no)
RU (2)	RU2655299C2 (no)
SI (1)	SI2833907T1 (no)
TR (1)	TR201806939T4 (no)
WO (1)	WO2013180834A2 (no)
ZA (1)	ZA201408100B (no)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ME03755B (me) *	2011-05-04	2021-04-20	Omeros Corp	Kompozicije za inhibiciju masp-2 zavisne aktivacije komplementa
MX2014015715A (es) *	2012-06-18	2016-02-05	Omeros Corp	Composiciones y metodos para inhibir masp-1 y/o masp-2 y/o masp-3 para el tratamiento de varias enfermedades y trastornos.
US20140363433A1 (en)	2013-03-15	2014-12-11	Omeros Corporation	Methods of Generating Bioactive Peptide-bearing Antibodies and Compositions Comprising the Same
WO2014144542A2 (en)	2013-03-15	2014-09-18	Omeros Corporation	Methods of generating bioactive peptide-bearing antibodies and compositions comprising the same
JOP20170154B1 (ar) *	2016-08-01	2023-03-28	Omeros Corp	تركيبات وطرق لتثبيط masp-3 لعلاج أمراض واضطرابات مختلفة
BR112019008265A2 (pt)	2016-11-28	2019-07-09	Chugai Pharmaceutical Co Ltd	molécula de ligação ao ligante cuja atividade de li-gação ao ligante é ajustável
MX2019005756A (es) *	2016-11-28	2019-08-14	Chugai Pharmaceutical Co Ltd	Dominio de union al antigeno y polipeptido que incluye seccion de transporte.
JP7409871B2 (ja) *	2017-04-03	2024-01-09	中外製薬株式会社	抗ｍａｓｐ－１抗体およびその使用方法
MX2020005220A (es)	2017-11-28	2020-08-24	Chugai Pharmaceutical Co Ltd	Polipeptido que incluye dominio de union al antigeno y seccion de transporte.
WO2019230867A1 (en)	2018-05-30	2019-12-05	Chugai Seiyaku Kabushiki Kaisha	Polypeptide comprising aggrecan binding domain and carrying moiety
PE20221033A1 (es) *	2019-07-31	2022-06-17	Biocryst Pharm Inc	Regimenes de dosificacion para inhibidores orales del factor d del complemento
MX2022006750A (es)	2019-12-04	2022-06-14	Omeros Corp	Inhibidores de masp-2 y metodos de uso.
EP4069676A1 (en)	2019-12-04	2022-10-12	Omeros Corporation	Masp-2 inhibitors and methods of use
IL293588A (en)	2019-12-04	2022-08-01	Omeros Corp	2-masp inhibitor compounds, preparations containing them and their uses
WO2022040149A1 (en)	2020-08-18	2022-02-24	Omeros Corporation	Monoclonal antibodies, compositions and methods for detecting complement factor d
CN114295594B (zh) *	2021-12-06	2023-09-19	贵州理工学院	一种基于分子信标筛选三螺旋DNA嵌入剂的“turn on”型荧光传感器

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4331647A (en)	1980-03-03	1982-05-25	Goldenberg Milton David	Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
US4676980A (en)	1985-09-23	1987-06-30	The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Target specific cross-linked heteroantibodies
US4946778A (en)	1987-09-21	1990-08-07	Genex Corporation	Single polypeptide chain binding molecules
US5223409A (en)	1988-09-02	1993-06-29	Protein Engineering Corp.	Directed evolution of novel binding proteins
US5211657A (en)	1988-11-07	1993-05-18	The United States Government As Represented By The Secretary Of The Department Of Health And Human Services	Laminin a chain deduced amino acid sequence, expression vectors and active synthetic peptides
US5530101A (en)	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
US5549910A (en)	1989-03-31	1996-08-27	The Regents Of The University Of California	Preparation of liposome and lipid complex compositions
EP0438803B1 (en)	1990-01-26	1997-03-12	Immunomedics, Inc.	Vaccines against cancer and infectious diseases
JP3218637B2 (ja)	1990-07-26	2001-10-15	大正製薬株式会社	安定なリポソーム水懸濁液
JP2958076B2 (ja)	1990-08-27	1999-10-06	株式会社ビタミン研究所	遺伝子導入用多重膜リポソーム及び遺伝子捕捉多重膜リポソーム製剤並びにその製法
ATE199392T1 (de)	1992-12-04	2001-03-15	Medical Res Council	Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
US5856121A (en)	1994-02-24	1999-01-05	Case Western Reserve University	Growth arrest homebox gene
US6074642A (en)	1994-05-02	2000-06-13	Alexion Pharmaceuticals, Inc.	Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
US5741516A (en)	1994-06-20	1998-04-21	Inex Pharmaceuticals Corporation	Sphingosomes for enhanced drug delivery
US5795587A (en)	1995-01-23	1998-08-18	University Of Pittsburgh	Stable lipid-comprising drug delivery complexes and methods for their production
US5731168A (en)	1995-03-01	1998-03-24	Genentech, Inc.	Method for making heteromultimeric polypeptides
US5738868A (en)	1995-07-18	1998-04-14	Lipogenics Ltd.	Liposome compositions and kits therefor
WO2001040451A2 (en) *	1999-12-02	2001-06-07	Jens Christian Jensenius	Masp-3, a complement-fixing enzyme, and uses for it
SG98393A1 (en)	2000-05-19	2003-09-19	Inst Materials Research & Eng	Injectable drug delivery systems with cyclodextrin-polymer based hydrogels
US7043719B2 (en) *	2001-07-23	2006-05-09	Intel Corporation	Method and system for automatically prioritizing and analyzing performance data for one or more, system configurations
CN100519643C (zh)	2002-07-19	2009-07-29	奥默罗斯公司	可生物降解的三嵌段共聚物,它们的合成方法和从它制得的水凝胶和生物材料
US7666627B2 (en) *	2002-08-08	2010-02-23	Targetex Kft.	Folded recombinant catalytic fragments of multidomain serine proteases, preparation and uses thereof
CA2515453C (en) *	2003-02-21	2013-09-24	Tanox, Inc.	Methods for preventing and treating tissue damage associated with ischemia-reperfusion injury
WO2005075665A2 (en) *	2004-02-03	2005-08-18	Bayer Healthcare Ag	Diagnostics and therapeutics for diseases associated with plasma kallikrein (klkb1)
US20050169921A1 (en) *	2004-02-03	2005-08-04	Leonard Bell	Method of treating hemolytic disease
US7803931B2 (en) *	2004-02-12	2010-09-28	Archemix Corp.	Aptamer therapeutics useful in the treatment of complement-related disorders
US7919094B2 (en)	2004-06-10	2011-04-05	Omeros Corporation	Methods for treating conditions associated with MASP-2 dependent complement activation
US8840893B2 (en) *	2004-06-10	2014-09-23	Omeros Corporation	Methods for treating conditions associated with MASP-2 dependent complement activation
US7612181B2 (en)	2005-08-19	2009-11-03	Abbott Laboratories	Dual variable domain immunoglobulin and uses thereof
EP1928506A4 (en)	2005-08-19	2009-10-21	Abbott Lab	IMMUNOGLOBULIN HAVING TWO VARIABLE DOMAINS AND USES THEREOF
DE602006004582D1 (de) *	2006-07-31	2009-02-12	Fiat Ricerche	Durch eine Fluidströmung betätigbarer elektrischer Generator
EP2152861B1 (en)	2007-05-31	2017-03-22	University of Washington	Inducible mutagenesis of target genes
EP2342231A1 (en) *	2008-09-26	2011-07-13	Roche Glycart AG	Bispecific anti-egfr/anti-igf-1r antibodies
CN102307594A (zh) *	2009-01-06	2012-01-04	戴埃克斯有限公司	用激肽释放酶抑制剂治疗粘膜炎
KR20110134415A (ko) *	2009-03-05	2011-12-14	스미스 앤드 네퓨, 인크.	대퇴경부 안내 와이어를 배치하기 위한 시스템, 방법 및 장치
EP2454281B1 (en) *	2009-07-17	2018-11-14	Omeros Corporation	Masp isoforms as inhibitors of complement activation
CN102958535A (zh)	2009-11-05	2013-03-06	亚力史剑桥公司	阵发性夜间血红蛋白尿、溶血性贫血和涉及血管内和血管外溶血的疾病状态的治疗
AU2012239889B2 (en) *	2011-04-08	2015-09-03	Omeros Corporation	Methods for treating conditions associated with MASP-2 dependent complement activation

2013
- 2013-04-05 IN IN2324KON2014 patent/IN2014KN02324A/en unknown
- 2013-04-05 DK DK18158799.9T patent/DK3366307T3/da active
- 2013-04-05 ES ES13798222.9T patent/ES2670668T3/es active Active
- 2013-04-05 CA CA2869326A patent/CA2869326C/en active Active
- 2013-04-05 AU AU2013267909A patent/AU2013267909B2/en active Active
- 2013-04-05 JP JP2015504751A patent/JP6366571B2/ja active Active
- 2013-04-05 PT PT137982229T patent/PT2833907T/pt unknown
- 2013-04-05 RS RS20180586A patent/RS57266B1/sr unknown
- 2013-04-05 NZ NZ629675A patent/NZ629675A/en unknown
- 2013-04-05 EP EP13798222.9A patent/EP2833907B1/en active Active
- 2013-04-05 RU RU2014144621A patent/RU2655299C2/ru active
- 2013-04-05 KR KR1020207022397A patent/KR102318623B1/ko active IP Right Grant
- 2013-04-05 EP EP18158799.9A patent/EP3366307B1/en active Active
- 2013-04-05 PL PL18158799T patent/PL3366307T3/pl unknown
- 2013-04-05 LT LTEP13798222.9T patent/LT2833907T/lt unknown
- 2013-04-05 WO PCT/US2013/035488 patent/WO2013180834A2/en active Application Filing
- 2013-04-05 BR BR112014024793A patent/BR112014024793A2/pt not_active Application Discontinuation
- 2013-04-05 MX MX2014012045A patent/MX357540B/es active IP Right Grant
- 2013-04-05 KR KR1020147030787A patent/KR102142508B1/ko active IP Right Grant
- 2013-04-05 RU RU2018114903A patent/RU2018114903A/ru unknown
- 2013-04-05 CN CN201380029994.3A patent/CN104661676A/zh active Pending
- 2013-04-05 PL PL13798222T patent/PL2833907T3/pl unknown
- 2013-04-05 NZ NZ781091A patent/NZ781091A/en unknown
- 2013-04-05 US US13/857,391 patent/US20130273053A1/en not_active Abandoned
- 2013-04-05 SI SI201331032T patent/SI2833907T1/en unknown
- 2013-04-05 TR TR2018/06939T patent/TR201806939T4/tr unknown
- 2013-04-05 MX MX2018008658A patent/MX2018008658A/es unknown
- 2013-04-05 ES ES18158799T patent/ES2894944T3/es active Active
- 2013-04-05 CA CA3087933A patent/CA3087933A1/en active Pending
- 2013-04-05 HU HUE13798222A patent/HUE036930T2/hu unknown
- 2013-04-05 DK DK13798222.9T patent/DK2833907T3/en active
2014
- 2014-10-05 IL IL234991A patent/IL234991B/en active IP Right Grant
- 2014-10-06 CL CL2014002694A patent/CL2014002694A1/es unknown
- 2014-11-05 ZA ZA2014/08100A patent/ZA201408100B/en unknown
- 2014-12-04 NO NO14196403A patent/NO2881536T3/no unknown
2015
- 2015-08-10 HK HK15107717.0A patent/HK1206996A1/xx unknown
2018
- 2018-01-31 AU AU2018200721A patent/AU2018200721B2/en active Active
- 2018-04-26 HR HRP20180671TT patent/HRP20180671T1/hr unknown
- 2018-05-23 CY CY181100540T patent/CY1120736T1/el unknown
- 2018-07-03 JP JP2018126460A patent/JP6815355B2/ja active Active
2019
- 2019-02-26 US US16/285,741 patent/US20190382505A1/en not_active Abandoned
2020
- 2020-05-17 IL IL274721A patent/IL274721B/en unknown
- 2020-06-22 AU AU2020204163A patent/AU2020204163A1/en not_active Abandoned
- 2020-09-17 JP JP2020156216A patent/JP2021001199A/ja active Pending
2021
- 2021-10-11 US US17/498,521 patent/US20220242972A1/en active Pending

Also Published As

Publication number	Publication date
EP2833907B1 (en)	2018-02-28
LT2833907T (lt)	2018-06-11
CA3087933A1 (en)	2013-12-05
IL234991A0 (en)	2014-12-31
BR112014024793A2 (pt)	2019-08-27
AU2013267909B2 (en)	2018-03-01
IL274721A (en)	2020-07-30
AU2018200721A1 (en)	2018-02-22
SI2833907T1 (en)	2018-07-31
IN2014KN02324A (no)	2015-05-01
MX2018008658A (es)	2021-10-19
CN104661676A (zh)	2015-05-27
EP3366307B1 (en)	2021-07-28
CY1120736T1 (el)	2019-12-11
NZ629675A (en)	2017-02-24
PL2833907T3 (pl)	2018-08-31
JP6366571B2 (ja)	2018-08-01
EP2833907A4 (en)	2016-03-16
AU2020204163A1 (en)	2020-07-09
WO2013180834A3 (en)	2014-04-03
PL3366307T3 (pl)	2022-03-07
AU2018200721B2 (en)	2020-03-26
WO2013180834A2 (en)	2013-12-05
RU2014144621A (ru)	2016-05-27
CL2014002694A1 (es)	2015-08-28
KR20150003785A (ko)	2015-01-09
JP2021001199A (ja)	2021-01-07
NZ727063A (en)	2021-10-29
CA2869326C (en)	2021-09-21
JP2018162307A (ja)	2018-10-18
RU2655299C2 (ru)	2018-05-24
KR102318623B1 (ko)	2021-11-02
MX2014012045A (es)	2015-05-15
TR201806939T4 (tr)	2018-06-21
IL274721B (en)	2022-04-01
EP2833907A2 (en)	2015-02-11
US20130273053A1 (en)	2013-10-17
RU2018114903A3 (no)	2021-08-12
EP3366307A1 (en)	2018-08-29
ZA201408100B (en)	2022-05-25
DK3366307T3 (da)	2021-11-01
HUE036930T2 (hu)	2018-08-28
KR102142508B1 (ko)	2020-08-10
ES2670668T3 (es)	2018-05-31
IL234991B (en)	2020-06-30
AU2013267909A1 (en)	2014-11-27
RU2018114903A (ru)	2019-03-04
DK2833907T3 (en)	2018-05-28
US20220242972A1 (en)	2022-08-04
PT2833907T (pt)	2018-05-29
US20190382505A1 (en)	2019-12-19
KR20200097808A (ko)	2020-08-19
ES2894944T3 (es)	2022-02-16
MX357540B (es)	2018-07-13
JP2015514117A (ja)	2015-05-18
NZ781091A (en)	2022-04-29
CA2869326A1 (en)	2013-12-05
HK1206996A1 (en)	2016-01-22
RS57266B1 (sr)	2018-08-31
JP6815355B2 (ja)	2021-01-20
HRP20180671T1 (hr)	2018-07-13

Publication	Publication Date	Title
BR112014017635A2 (no)	2017-06-20
BR112014017614A2 (no)	2017-06-20
BR112014017625A2 (no)	2017-06-20
BR112014017592A2 (no)	2017-06-20
BR112014017659A2 (no)	2017-06-20
BR112014017646A2 (no)	2017-06-20
BR112014017638A2 (no)	2017-06-20
BR112014017607A2 (no)	2017-06-20
BR112013027865A2 (no)	2017-01-03
BR112014017634A2 (no)	2017-06-20
BR112014017609A2 (no)	2017-06-20
BR112014017644A2 (no)	2017-06-20
RU2018114903A3 (no)	2021-08-12
BR112014017588A2 (no)	2017-06-20
BR112014017647A2 (no)	2017-06-20
BR112014013184A8 (no)	2017-06-27
BR112014017618A2 (no)	2017-06-20
BR112014017630A2 (no)	2017-06-20
BR112014017652A2 (no)	2017-06-20
BR112014017621A2 (no)	2017-06-20
BR112014017622A2 (no)	2017-06-20
BR112014017627A2 (no)	2017-06-20
BR112014017623A2 (no)	2017-06-20
BR112014017631A2 (no)	2017-06-20
BR112014017641A2 (no)	2017-06-20